$TEVA News

Teva to Present at the Goldman Sachs Global Healthcare Conference

Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks

TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings

A Look At Teva (TEVA) Valuation After New Real World Tardive Dyskinesia Data Release

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today

TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EU

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Teva TD Findings Highlight Underdiagnosis And Shape Neuroscience Growth Story

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

Teva Pharmaceutical Industries Announces New Data Highlighting Significant Gap In Diagnosing Tardive Dyskinesia In Teen Patients With Underlying Mood Disorders

Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal

Is It Too Late To Consider Teva Pharmaceutical Industries (TEVA) After Its 3‑Year Rally?

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $40

UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42

Piper Sandler Reiterates Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42

Truist Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $45

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan